Alexandra Thomas1, Anthony Rhoads2, Jonathan Suhl2, Kristin M Conway2, William G Hundley3, Lacey R McNally4, Jacob Oleson5, Susan A Melin1, Charles F Lynch2, Paul A Romitti6. 1. Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC. 2. Department of Epidemiology, University of Iowa, Iowa City, IA. 3. Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA. 4. Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC. 5. Department of Biostatistics, University of Iowa, Iowa City, IA. 6. Department of Epidemiology, University of Iowa, Iowa City, IA; Department of Biostatistics, University of Iowa, Iowa City, IA. Electronic address: paul-romitti@uiowa.edu.
Abstract
BACKGROUND: Young premenopausal women with breast cancer often experience more aggressive disease biology and poorer survival than older women. Diagnostic and therapeutic advances, including human epidermal growth factor receptor 2 (HER2)-directed therapy, may lessen treatment burden and improve survival for these young women, but contemporary incidence and survival data by HER2 status are limited. PATIENTS AND METHODS: We identified women aged 20-49 years (n = 68,530) diagnosed with stage I-III breast cancer during 2010-2016 from the United States Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted average annual percent changes in incidence (diagnosis 2010-2016) and 5-year Kaplan-Meier survival curves (diagnosis 2010-2015) were estimated by HER2 and hormone receptor (HR) status and stratified independently by cancer stage and race/ethnicity. RESULTS: With increasing age decade, proportions of HER2-/HR+ cancer increased, whereas proportions of HER2+/HR+, HER2+/HR-, and HER2-/HR- decreased. The greatest increases in incidence during 2010-2016 were observed for HER2+ among women aged 20-49 years and HER2-/HR- among women aged 20-29 years. Incidence decreased for HER2-/HR- among women aged 40-49 years. Five-year survival was lowest for HER2-/HR- status compared to other receptor-based subtypes among women aged 20-49 years. HER2+ status was more beneficial for 5-year survival than HR+ status among women aged 20-29 years, with the opposite observed among women aged 30-49 years, particularly those aged 40-49 years. CONCLUSION: HER2+ breast cancer increased among premenopausal women and was also associated with higher early survival within each HR status. HER2-/HR- cancer also increased among women aged 20-29 years and was associated with lower early survival. Our contemporary data provide important insights to help inform preventive and therapeutic strategies for premenopausal women.
BACKGROUND: Young premenopausal women with breast cancer often experience more aggressive disease biology and poorer survival than older women. Diagnostic and therapeutic advances, including humanepidermal growth factor receptor 2 (HER2)-directed therapy, may lessen treatment burden and improve survival for these young women, but contemporary incidence and survival data by HER2 status are limited. PATIENTS AND METHODS: We identified women aged 20-49 years (n = 68,530) diagnosed with stage I-III breast cancer during 2010-2016 from the United States Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted average annual percent changes in incidence (diagnosis 2010-2016) and 5-year Kaplan-Meier survival curves (diagnosis 2010-2015) were estimated by HER2 and hormone receptor (HR) status and stratified independently by cancer stage and race/ethnicity. RESULTS: With increasing age decade, proportions of HER2-/HR+ cancer increased, whereas proportions of HER2+/HR+, HER2+/HR-, and HER2-/HR- decreased. The greatest increases in incidence during 2010-2016 were observed for HER2+ among women aged 20-49 years and HER2-/HR- among women aged 20-29 years. Incidence decreased for HER2-/HR- among women aged 40-49 years. Five-year survival was lowest for HER2-/HR- status compared to other receptor-based subtypes among women aged 20-49 years. HER2+ status was more beneficial for 5-year survival than HR+ status among women aged 20-29 years, with the opposite observed among women aged 30-49 years, particularly those aged 40-49 years. CONCLUSION:HER2+ breast cancer increased among premenopausal women and was also associated with higher early survival within each HR status. HER2-/HR- cancer also increased among women aged 20-29 years and was associated with lower early survival. Our contemporary data provide important insights to help inform preventive and therapeutic strategies for premenopausal women.
Authors: Miguel Martin; Frankie A Holmes; Bent Ejlertsen; Suzette Delaloge; Beverly Moy; Hiroji Iwata; Gunter von Minckwitz; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Zorica Tomašević; Neelima Denduluri; Robert Šeparović; Erhan Gokmen; Anna Bashford; Manuel Ruiz Borrego; Sung-Bae Kim; Erik Hugger Jakobsen; Audrone Ciceniene; Kenichi Inoue; Friedrich Overkamp; Joan B Heijns; Anne C Armstrong; John S Link; Anil Abraham Joy; Richard Bryce; Alvin Wong; Susan Moran; Bin Yao; Feng Xu; Alan Auerbach; Marc Buyse; Arlene Chan Journal: Lancet Oncol Date: 2017-11-13 Impact factor: 41.316
Authors: L C Collins; J D Marotti; S Gelber; K Cole; K Ruddy; S Kereakoglow; E F Brachtel; L Schapira; S E Come; E P Winer; A H Partridge Journal: Breast Cancer Res Treat Date: 2011-11-13 Impact factor: 4.872
Authors: Rachel J D Cossetti; Scott K Tyldesley; Caroline H Speers; Yvonne Zheng; Karen A Gelmon Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: Ann H Partridge; Shari Gelber; Martine J Piccart-Gebhart; Florine Focant; Matthew Scullion; Eileen Holmes; Eric P Winer; Richard D Gelber Journal: J Clin Oncol Date: 2013-06-10 Impact factor: 44.544
Authors: Hazel B Nichols; Minouk J Schoemaker; Jianwen Cai; Jiawei Xu; Lauren B Wright; Mark N Brook; Michael E Jones; Hans-Olov Adami; Laura Baglietto; Kimberly A Bertrand; William J Blot; Marie-Christine Boutron-Ruault; Miren Dorronsoro; Laure Dossus; A Heather Eliassen; Graham G Giles; Inger T Gram; Susan E Hankinson; Judy Hoffman-Bolton; Rudolf Kaaks; Timothy J Key; Cari M Kitahara; Susanna C Larsson; Martha Linet; Melissa A Merritt; Roger L Milne; Valeria Pala; Julie R Palmer; Petra H Peeters; Elio Riboli; Malin Sund; Rulla M Tamimi; Anne Tjønneland; Antonia Trichopoulou; Giske Ursin; Lars Vatten; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Wei Zheng; Clarice R Weinberg; Anthony J Swerdlow; Dale P Sandler Journal: Ann Intern Med Date: 2018-12-11 Impact factor: 25.391
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Braden Miller; Hunter Chalfant; Alexandra Thomas; Elizabeth Wellberg; Christina Henson; Molly W McNally; William E Grizzle; Ajay Jain; Lacey R McNally Journal: Int J Mol Sci Date: 2021-03-09 Impact factor: 5.923